Study of Cell-surface Proteins in Renal Tumors for Future Exploration of New Anticancer Therapies


About this study

In this study, we propose to use a combination of cell-surface capture and mass spectrometry on patient tumors to identify tumor-associated cell-surface proteins that are targetable with next-generation immunotherapies. These therapeutic antibodies and their derivatives have transformed the therapeutic landscape of cancer patients. Only 20% of cell-surface proteins have been investigated so far for drug development. Untargeted proteomics has been the gold standard to identify tumor-associated proteins. However, it suffers from low sensitivity for cell-surface proteins. Cytosolic proteins are much more abundant and soluble than cell-surface proteins which results in limited resolution of the entire cell-surface proteome.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18+.
  • Able to give informed consent.
  • Newly diagnosed clear-cell renal cell carcinoma.
  • Eligible for radical nephrectomy.

Exclusion Criteria:

  • Unable or unwilling to provide informed consent.
  • No previous systemic therapy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Fabrice Lucien-Matteoni, Ph.D.

Open for enrollment

Contact information:

Kathryn Barthels B.S.

(507) 538-5772

More information


Publications are currently not available

Mayo Clinic Footer